Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cogstate Ltd ( (AU:CGS) ) just unveiled an announcement.
Cogstate Ltd has updated its financial guidance for the half-year ending December 2025, highlighting strong sales contract performance despite timing-related revenue deferrals impacting short-term revenue and profitability. The company expects to execute sales contracts worth $37-$40 million, marking significant growth compared to the previous period. However, revenue recognition is delayed due to late contract signings and a shift in revenue mix, with service fee revenue expected to grow over the trial’s life. Despite reduced revenue expectations for 1H26, Cogstate remains confident in its growth strategy, driven by investments in new offerings and expansion into psychiatry and mood disorders, particularly in the Asia-Pacific region. The company anticipates improved margins in 2H26 as revenue from increased sales contracts is recognized, reinforcing its competitive position and growth potential.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd operates in the clinical trials industry, providing technology and services to pharmaceutical and biotechnology companies. The company focuses on central nervous system clinical trials, offering solutions for Alzheimer’s disease, other dementias, Parkinson’s disease, psychiatry, schizophrenia, sleep disorders, and rare diseases.
Average Trading Volume: 291,394
Technical Sentiment Signal: Buy
Current Market Cap: A$435.9M
For an in-depth examination of CGS stock, go to TipRanks’ Overview page.